Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs
Ist Teil von
American journal of physiology. Heart and circulatory physiology, 1994-01, Vol.266 (1), p.H99-H106
Ort / Verlag
United States
Erscheinungsjahr
1994
Quelle
MEDLINE
Beschreibungen/Notizen
J. F. Liard
Department of Physiology, Medical College of Wisconsin, Milwaukee 53226.
Experiments were performed in conscious chronically instrumented dogs to
study the mechanism of hemodynamic effects mediated by selective
vasopressin V2 agonists. In one group of dogs (n = 5) instrumented for the
measurement of arterial pressure and cardiac output (electromagnetic
flowmeter), the infusion of NG-nitro-L-arginine methyl ester (L-NAME; 20 or
40 micrograms.kg-1 x min-1) prevented or significantly inhibited the
increase in cardiac output, heart rate and systemic conductance induced by
injections of 1-desamino-8-D-arginine vasopressin (DDAVP, desmopressin) and
4-valine-8-D-arginine vasopressin (VDAVP), two selective V2 agonists.
L-NAME infusion did not modify the aortic adenosine 3',5'-cyclic
monophosphate increase induced by DDAVP infusion. In a second group of dogs
similarly prepared (n = 4), the administration of L-arginine (10 mg.kg-1 x
min-1) at the same time as that of L-NAME (20 micrograms.kg-1 x min-1)
completely prevented the hemodynamic effects of L-NAME and restored the
response to DDAVP administration. In a third group of dogs (n = 4), the
infusion of a bradykinin B2 antagonist, at a rate that significantly
inhibited the cardiac output, heart rate, and blood pressure responses to
bradykinin, did not modify the hemodynamic response to DDAVP infusion. We
conclude that the hemodynamic effects of selective V2 agonists in dogs are
not mediated by bradykinin release but instead via a V2-like receptor on
endothelial cells that triggers the release of nitric oxide.